Chapter 7.3
Clinical Manifestations and Management of Bleeding Episodes in Cirrhotics
Jaime Bosch,
Juan G. Abraldes,
Juan Carlos García-Pagán,
Jaime Bosch
Search for more papers by this authorJuan G. Abraldes
Search for more papers by this authorJuan Carlos García-Pagán
Search for more papers by this authorJaime Bosch,
Juan G. Abraldes,
Juan Carlos García-Pagán,
Jaime Bosch
Search for more papers by this authorJuan G. Abraldes
Search for more papers by this authorJuan Carlos García-Pagán
Search for more papers by this authorBook Editor(s):Juan Rodés MD,
Jean-Pierre Benhamou MD,
Andres T. Blei MD,
Jürg Reichen MD,
Mario Rizzetto MD,
Juan Rodés MD
Director General, Hospital Clinic; Professor of Medicine, University of Barcelona, Barcelona, Spain
Search for more papers by this authorJean-Pierre Benhamou MD
Professor of Hepatology, Université Denis Diderot Paris 7, Assistance Publique — Hôpitaux de Paris and Inserm U773, Service d'Hépatologie, Hôpital Beaujon, Clichy, France
Search for more papers by this authorAndres T. Blei MD
Professor of Medicine and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJürg Reichen MD
Professor of Medicine, University of Bern; Chief of Hepatology, University Hospital, Bern, Switzerland
Search for more papers by this authorMario Rizzetto MD
Professor of Gastroenterology, University of Turin, Turin, Italy
Search for more papers by this author
References
- D'Amico G (2004) Esophageal varices: from appearance to rupture; natural history and prognostic indicators. In: RJ Groszmann, J Bosch (eds) Portal Hypertension in the 21st Century. Dordrecht: Kluwer Academic Publishers, pp. 147–154.
- Christensen E, Fauerholdt L, Schlichting P et al. (1981) Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone. Gastroenterology 81, 944–952.
- D'Amico G, Luca A (1997) Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 11, 243–256.
- de Franchis R, Primignani M (2001) Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 5, 645–663.
- Merli M, Nicolini G, Angeloni S et al. (2003) Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38, 266–272.
- Groszmann RJ, Garcia-Tsao G, Bosch J et al. (2005) Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353, 2254–2261.
- De Franchis R (2003) Evaluation and follow-up of patients with cirrhosis and oesophageal varices. J Hepatol 38, 361–363.
- Zoli M, Merkel C, Magalotti D et al. (2000) Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastroenterol 95, 503–508.
- Merkel C, Marin R, Angeli P et al. (2004) A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 127, 476–484.
- Cales P, Desmorat H, Vinel JP et al. (1990) Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. Gut 31, 1298–1302.
- Vorobioff J, Groszmann RJ, Picabea E et al. (1996) Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 111, 701–709.
- Groszmann RJ, Bosch J, Grace ND et al. (1990) Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage (see comments). Gastroenterology 99, 1401–1407.
- D'Amico G, Pagliaro L, Bosch J (1999) Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19, 475–505.
- NIEC (1988) Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices (see comments). N Engl J Med 319, 983–989.
- Merkel C, Zoli M, Siringo S et al. (2000) Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index (in process citation). Am J Gastroenterol 95, 2915–2920.
- D'Amico G, De Franchis R (2003) Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 38, 599–612.
- Merican I, Sprengers D, McCormick PA et al. (1993) Diurnal pattern of variceal bleeding in cirrhotic patients. J Hepatol 19, 15–22.
- Garcia-Pagan JC, Feu F, Castells A et al. (1994) Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. Hepatology 19, 595–601.
- de Franchis R (2005) Evolving consensus in portal hypertension. Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43, 167–176.
- Graham D, Smith J (1981) The course of patients after variceal hemorrhage. Gastroenterology 80, 800–806.
- Bernard B, Cadranel JF, Valla D et al. (1995) Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 108, 1828–1834.
- Goulis J, Armonis A, Patch D et al. (1998) Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 27, 1207–1212.
- Vivas S, Rodriguez M, Palacio MA et al. (2001) Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 46, 2752–2757.
- Ben Ari Z, Cardin F, McCormick AP et al. (1999) A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol 31, 443–450.
- Moitinho E, Escorsell A, Bandi JC et al. (1999) Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 117, 626–631.
- Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L et al. (2004) Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 40, 793–801.
- Carbonell N, Pauwels A, Serfaty L et al. (2004) Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 40, 652–659.
- Nidegger D, Ragot S, Berthelemy P et al. (2003) Cirrhosis and bleeding: the need for very early management. J Hepatol 39, 509–514.
- Gatta A, Merkel C, Amodio P et al. (1994) Development and validation of a prognostic index predicting death after upper gastrointestinal bleeding in patients with liver cirrhosis: a multicenter study. Am J Gastroenterol 89, 1528–1536.
- del Olmo JA, Pena A, Serra MA et al. (2000) Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 32, 19–24.
- Cardenas A, Gines P, Uriz J et al. (2001) Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 34, 671–676.
- Grace ND, Groszmann RJ, Garcia-Tsao G et al. (1998) Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 28, 868–880.
- de Franchis R (2000) Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 33, 846–852.
- Feu F, Garcia-Pagan JC, Bosch J et al. (1995) Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346, 1056–1059.
- Abraldes JG, Tarantino I, Turnes J et al. (2003) Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37, 902–908.
- Viallet A, Marleau D, Huet M et al. (1975) Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 69, 1297–1300.
- Garcia-Tsao G, Groszmann RJ, Fisher RL et al. (1985) Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 5, 419–424.
- Casado M, Bosch J, Garcia-Pagan JC et al. (1998) Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114, 1296–1303.
- Merkel C, Bolognesi M, Sacerdoti D et al. (2000) The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 32, 930–934.
- Villanueva C, Balanzo J, Novella MT et al. (1996) Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 334, 1624–1629.
- Villanueva C, Minana J, Ortiz J et al. (2001) Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 345, 647–655.
- Escorsell A, Bordas JM, Castaneda B et al. (2000) Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 31, 1061–1067.
- Villanueva C, Lopez-Balaguer JM, Aracil C et al. (2004) Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 40, 757–765.
- Schrier RW, Arroyo V, Bernardi M et al. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151–1157.
- Groszmann RJ (1994) Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 20, 1359–1363.
- Garcia-Pagan JC, Salmeron JM, Feu F et al. (1994) Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 19, 1095–1099.
- de la Pena J, Brullet E, Sanchez-Hernandez E et al. (2005) Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 41, 572–578.
- Bosch J, Thabut D, Bendtsen F et al. (2004) Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 127, 1123–1130.
- Zaman A, Hapke R, Flora K et al. (1999) Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 94, 3292–3296.
- Chalasani N, Imperiale TF, Ismail A et al. (1999) Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol 94, 3285–3291.
- Madhotra R, Mulcahy HE, Willner I et al. (2002) Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol 34, 81–85.
- Giannini E, Botta F, Borro P et al. (2003) Platelet count/spleen diameter ratio, proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 52, 1200–1205.
- Saab S, DeRosa V, Nieto J et al. (2003) Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol 98, 763–770.
- Spiegel BM, Targownik L, Dulai GS et al. (2003) Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology 37, 366–377.
- Arguedas MR, Heudebert GR, Eloubeidi MA et al. (2002) Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol 97, 2441–2452.
- Lebrec D, Nouel O, Corbic M et al. (1980) Propranolol — a medical treatment for portal hypertension? Lancet 2, 180–182.
- Kroeger RJ, Groszmann RJ (1985) Effect of selective blockade of beta 2-adrenergic receptors on portal and systemic hemodynamics in a portal hypertensive rat model. Gastroenterology 88, 896–900.
- Gengo FM, Huntoon L, McHugh WB (1987) Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect. Arch Intern Med 147, 39–43.
- Wang T, Kaumann AJ, Brown MJ (1996) (-)-Timolol is a more potent antagonist of the positive inotropic effects of (-)-adrenaline than of those of (-)-noradrenaline in human atrium. Br J Clin Pharmacol 42, 217–223.
- Garcia-Pagan J, Morillas RM, Bañares R et al. (2003) Propranolol plus placebo vs propranolol plus isosorbide-5-mononitrate in the prevention of the first variceal bleed. A double blind RCT. Hepatology 37, 1260–1266.
- Garcia-Pagan JC, Villanueva C, Vila MC et al. (2001) Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 121, 908–914.
- Poynard T, Cales P, Pasta L et al. (1991) Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 324, 1532–1538.
- Bosch J (2005) Is treatment with nadolol effective against the growth of small esophageal varices in patients with cirrhosis' Nature Clin Pract Gastroenterol Hepatol 2, 18–19.
- Abraczinskas DR, Ookubo R, Grace ND et al. (2001) Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology 34, 1096–1102.
- Garcia-Pagan JC, Feu F, Bosch J et al. (1991) Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 114, 869–873.
- Merkel C, Sacerdoti D, Bolognesi M et al. (1997) Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 26, 34–39.
- Merkel C, Marin R, Enzo E et al. (1996) Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP) (see comments). Lancet 348, 1677–1681.
- Merkel C, Marin R, Sacerdoti D et al. (2000) Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 31, 324–329.
- Imperiale TF, Chalasani N (2001) A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology 33, 802–807.
- De BK, Ghoshal UC, Das T et al. (1999) Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 14, 220–224.
- Lui HF, Stanley AJ, Forrest EH et al. (2002) Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 123, 735–744.
- Schepke M, Kleber G, Nurnberg D et al. (2004) Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 40, 65–72.
- Lo GH, Chen WC, Chen MH et al. (2004) Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 59, 333–338.
- Sarin SK, Lamba GS, Kumar M et al. (1999) Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding (see comments). N Engl J Med 340, 988–993.
- Jutabha R, Jensen DM, Martin P et al. (2005) Randomized study comparing banding and propanolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 128, 870–881.
- Thuluvath PJ, Maheshwari A, Jagannath S et al. (2005) A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show a difference in bleeding rates. Dig Dis Sci 50, 407–410.
- Song H, Shin JW, Kim HI et al. (2000) A prospective randomized trial between the prophylactic endoscopic variceal ligation and propranolol administration for prevention of first bleeding in cirrhotic patients with high risk esophageal varices. J Hepatol 32 (Suppl. 2), 41A.
- Gheorghe C, Gheorghe L, Vadan R et al. (2002) Prophylactic banding ligation of high-risk esophageal varices in patients on the waiting list for liver transplantation: an interim analysis. J Hepatol 36 (Suppl. 1), 38A.
- Drastich P, Lata J, Petrtyl J et al. (2005) Endoscopic variceal band ligation in comparison with propranolol in prophylaxis of first variceal bleeding in patients with liver cirrhosis. J Hepatol 42, 202a.
- de la Mora, Farca-Belsaguy AA, Uribe M et al. (2000) Ligation vs propranolol for primary prophylaxis of variceal bleeding using multiple band ligator and objective measurements of treatment adequacy: preliminary results. Gastroenterology 118, 6511A.
- Chen CY, Sheu MZ, Su SY (1998) Prophylactic endoscopic variceal ligation for esophageal varices. Gastroenterology 114, 1224A.
- Turnes J, García-Pagán JC, Abraldes JG et al. (2003) Pharmacological reduction of portal pressure and long term risk of first variceal bleeding in patients with cirrhosis. Hepatology 38, 219A.
- Triantos C, Vlachogiannakos J, Armonis A et al. (2005) Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. Aliment Pharmacol Ther 21, 1435–1443.
- Sarin SK, Wadhawan M, Agarwal SR et al. (2005) Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 100, 797–804.
- D'Amico G, Pagliaro L, Bosch J (1995) The treatment of portal hypertension: a meta-analytic review. Hepatology 22, 332–354.
- Lebrec D, Nouel O, Bernuau J et al. (1981) Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet 1, 920–921.
- Pasta L, D'Amico G, Patti R (1999) Isosorbide mononitrate (IMN) with nadolol compared with nadolol alone for prevention of recurrent bleeding in cirrhosis. a double-blind placebo-controlled randomised trial. J Hepatol 30, 81A.
- Gournay J, Masliah C, Martin T et al. (2000) Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 31, 1239–1245.
- Bureau C, Peron JM, Alric L et al. (2002) ‘A la carte’ treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 36, 1361–1366.
- de Franchis R, Primignani M (1999) Endoscopic treatments for portal hypertension. Semin Liver Dis 19, 439–455.
- Laine L, el Newihi HM, Migikovsky B et al. (1993) Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 119, 1–7.
- Patch D, Sabin CA, Goulis J et al. (2002) A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 123, 1013–1019.
- Romero G, Kravetz D, Argonz J et al. (2006) Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. Aliment Pharmacol Ther 24, 601–611.
- Lo GH, Chen WC, Chen MH et al. (2002) Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 123, 728–734.
- Lo GH, Lai KH, Cheng JS et al. (2000) Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 32, 461–465.
- Burroughs AK, Vangeli M (2002) Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated metaanalysis. Scand J Gastroenterol 37, 249–252.
- Escorsell A, Banares R, Garcia-Pagan JC et al. (2002) TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 35, 385–392.
- Rosemurgy AS, Serafini FM, Zweibel BR et al. (2000) Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt: extended follow-up of an expanded randomized prospective trial. J Gastrointest Surg 4, 589–597.
- Henderson JM, Boyer TD, Kutner MH et al. (2006) Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology 130, 1643–1651.
- Bureau C, Garcia-Pagan JC, Otal P et al. (2004) Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: results of a randomized study. Gastroenterology 126, 469–475.
- McCormick PA, Jenkins SA, McIntyre N et al. (1995) Why portal hypertensive varices bleed and bleed: a hypothesis. Gut 36, 100–103.
- Castaneda B, Morales J, Lionetti R et al. (2001) Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 33, 821–825.
- Bernstein DE, Jeffers L, Erhardtsen E et al. (1997) Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 113, 1930–1937.
- Ejlersen E, Melsen T, Ingerslev J et al. (2001) Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 36, 1081–1085.
- Vivas S, Rodriguez M, Palacio MA et al. (2001) Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 46, 2752–2757.
- Hou MC, Lin HC, Liu TT et al. (2004) Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 39, 746–753.
- Bernard B, Grange JD, Khac EN et al. (1999) Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 29, 1655–1661.
- Rimola A, Garcia-Tsao G, Navasa M et al. (2000) Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 32, 142–153.
- Fernandez J, Ruiz del Arbol L, Serradilla R et al. (2006) Norfloxacin vs ceftriaxone in the prophylaxis of infections in cirrhotics with advanced cirrhosis and hemorrhage. Gastroenterology 131, 1049–1056.
- Levacher S, Letoumelin P, Pateron D et al. (1995) Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 346, 865–868.
- Abraldes JG, Bosch J (2002) Somatostatin and analogues in portal hypertension. Hepatology 35, 1305–1312.
- Bosch J, Lebrec D, Jenkins SA (1998) Development of analogues: successes and failures. Scand J Gastroenterol Suppl 226, 3–13.
- Escorsell A, Ruiz d'A, Planas R et al. (2000) Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology 32, 471–476.
- Ioannou GN, Doust J, Rockey DC (2003) Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 17, 53–64.
- Uriz J, Gines P, Cardenas A et al. (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33, 43–48.
- Tyden G, Sammegard H, Thulin L et al. (1978) Treatment of bleeding esophageal varices with somatostatin. N Engl J Med 299, 1466–1467.
- Bosch J, Kravetz D, Rodes J (1981) Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 80, 518–525.
- Escorsell A, Bordas JM, del Arbol LR et al. (1998) Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group. J Hepatol 29, 779–788.
- Moitinho E, Planas R, Bañares R et al. (2001) Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 35, 712–718.
- Valenzuela JE, Schubert T, Fogel MR et al. (1989) A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices (see comments). Hepatology 10, 958–961.
- Villanueva C, Ortiz J, Sabat M et al. (1999) Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Hepatology 30, 384–389.
- Escorsell A, Bandi JC, Andreu V et al. (2001) Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 120, 161–169.
- International Octreotide Varices Study Group and Burroughs AK (1996) Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial failures. Hepatology 24, 352A.
- Corley DA, Cello JP, Adkisson W et al. (2001) Octreotide for acute esophageal variceal bleeding: a meta-analysis. Gastroenterology 120, 946–954.
- Lo GH, Lai KH, Cheng JS et al. (1997) Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices. Hepatology 25, 1101–1104.
- Villanueva C, Morales J, Lionetti R et al. (2001) A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 45, 560–567.
- Avgerinos A, Armonis A, Stefanidis G et al. (2004) Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology 39, 1623–1630.
- Avgerinos A, Nevens F, Raptis S et al. (1997) Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 350, 1495–1499.
- Cales P, Masliah C, Bernard B et al. (2001) Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. N Engl J Med 344, 23–28.
- Banares R, Albillos A, Rincon D et al. (2002) Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 35, 609–615.
- D'Amico G, Pietrosi G, Tarantino I et al. (2003) Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 124, 1277–1291.
- Burroughs AK, Patch D (1999) Transjugular intrahepatic portosystemic shunt. Semin Liver Dis 19, 457–473.
- Bosch J (2001) Salvage transjugular intrahepatic portosystemic shunt: is it really life-saving? J Hepatol 35, 658–660.
- Henderson JM (2001) Salvage therapies for refractory variceal hemorrhage. Clin Liver Dis 5, 709–725.
- Patch D, Nikolopoulou V, McCormick A et al. (1998) Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. J Hepatol 28, 454–460.
- Sarin SK, Lahoti D, Saxena SP et al. (1992) Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 16, 1343–1349.
- Teres J, Cecilia A, Bordas JM et al. (1978) Esophageal tamponade for bleeding varices. Controlled trial between the Sengstaken-Blakemore tube and the Linton-Nachlas tube. Gastroenterology 75, 566–569.
- Panes J, Teres J, Bosch J et al. (1988) Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes. Dig Dis Sci 33, 454–459.
- Sarin SK, Agarwal SR (2001) Gastric varices and portal hypertensive gastropathy. Clin Liver Dis 5, 727–767, x.
- Huang YH, Yeh HZ, Chen GH et al. (2000) Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. Gastrointest Endosc 52, 160–167.
- Lee YT, Chan FK, Ng EK et al. (2000) EUS-guided injection of cyanoacrylate for bleeding gastric varices. Gastrointest Endosc 52, 168–174.
- Kind R, Guglielmi A, Rodella L et al. (2000) Bucrylate treatment of bleeding gastric varices: 12 years' experience. Endoscopy 32, 512–519.
- Lo GH, Lai KH, Cheng JS et al. (2001) A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 33, 1060–1064.
- Sarin SK, Jain AK, Jain M et al. (2002) A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 97, 1010–1015.
- Heneghan MA, Byrne A, Harrison PM (2002) An open pilot study of the effects of a human fibrin glue for endoscopic treatment of patients with acute bleeding from gastric varices. Gastrointest Endosc 56, 422–426.
- Yang WL, Tripathi D Therapondos G et al. (2002) Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol 97, 1381–1385.
- Chau TN, Patch D, Chan YW et al. (1998) ‘Salvage’ transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 114, 981–987.
- Barange K, Peron JM, Imani K et al. (1999) Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology 30, 1139–1143.
- Primignani M, Carpinelli L, Preatoni P et al. (2000) Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology 119, 181–187.
- Perez-Ayuso RM, Pique JM, Bosch J et al. (1991) Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 337, 1431–1434.
- Panes J, Bordas JM, Pique JM et al. (1993) Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Hepatology 17, 213–218.
- Panes J, Pique JM, Bordas JM et al. (1994) Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology 19, 55–60.
- Panes J, Pique JM, Bordas JM et al. (1994) Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 20, 336–341.
- Panes J, Casadevall M, Fernandez M et al. (1994) Gastric microcircu-latory changes of portal-hypertensive rats can be attenuated by long-term estrogen-progestagen treatment. Hepatology 20, 1261–1270.
- Kouroumalis EA, Koutroubakis IE, Manousos ON (1998) Somatostatin for acute severe bleeding from portal hypertensive gastropathy. Eur J Gastroenterol Hepatol 10, 509–512.
- Orloff MJ, Orloff MS, Orloff SL et al. (1995) Treatment of bleeding from portal hypertensive gastropathy by portacaval shunt. Hepatology 21, 1011–1017.
- Urata J, Yamashita Y, Tsuchigame T et al. (1998) The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol 13, 1061–1067.
- Kamath PS, Lacerda M, Ahlquist DA et al. (2000) Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 118, 905–911.
